BRPI0513866A - composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação - Google Patents

composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação

Info

Publication number
BRPI0513866A
BRPI0513866A BRPI0513866-3A BRPI0513866A BRPI0513866A BR PI0513866 A BRPI0513866 A BR PI0513866A BR PI0513866 A BRPI0513866 A BR PI0513866A BR PI0513866 A BRPI0513866 A BR PI0513866A
Authority
BR
Brazil
Prior art keywords
microparticles
composition
inhalation device
pulmonary hypertension
treatment
Prior art date
Application number
BRPI0513866-3A
Other languages
English (en)
Inventor
Curtis Ruegg
Julian A Blair
Original Assignee
Cotherix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cotherix Inc filed Critical Cotherix Inc
Publication of BRPI0513866A publication Critical patent/BRPI0513866A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO, MICROPARTìCULAS, MéTODO PARA O TRATAMENTO DA HIPERTENSãO PULMONAR, E, DISPOSITIVO DE INALAçãO São expostas micropartículas compreendendo iloprost. Em algumas modalidades, as micropartículas são usadas para tratar hipertensão pulmonar. Dispositivos que compreendem as micropartículas são também usados. Terapias combinadas, que utilizam as micropartículas, são também providas.
BRPI0513866-3A 2004-07-26 2005-07-26 composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação BRPI0513866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59125304P 2004-07-26 2004-07-26
PCT/US2005/026449 WO2006014930A2 (en) 2004-07-26 2005-07-26 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation

Publications (1)

Publication Number Publication Date
BRPI0513866A true BRPI0513866A (pt) 2008-05-20

Family

ID=35169689

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513866-3A BRPI0513866A (pt) 2004-07-26 2005-07-26 composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação

Country Status (13)

Country Link
US (1) US20060147520A1 (pt)
EP (1) EP1796653A2 (pt)
JP (1) JP2008507585A (pt)
KR (1) KR20070054644A (pt)
CN (1) CN101090714A (pt)
AU (1) AU2005269465A1 (pt)
BR (1) BRPI0513866A (pt)
CA (1) CA2574958A1 (pt)
IL (1) IL180851A0 (pt)
MX (1) MX2007000979A (pt)
NO (1) NO20071090L (pt)
RU (1) RU2007106714A (pt)
WO (1) WO2006014930A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006247077A1 (en) * 2005-05-18 2006-11-23 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
US20080305176A1 (en) * 2006-01-24 2008-12-11 Biocompatibles Uk Limited Process For Loading Polymer Particles With Drug
EP2026816B1 (en) * 2006-05-15 2018-10-24 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
AU2008259768B2 (en) * 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
EP2237788A4 (en) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
WO2009103068A1 (en) 2008-02-15 2009-08-20 Life Technologies Corporation Methods and compositions for shearing of polymers by sonication
WO2009105445A1 (en) * 2008-02-18 2009-08-27 Virginia Commonwealth University Effective delivery of nanoparticles and micrometer-sized pharmaceutical aerosols to the lung through enhanced condensational growth
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
CA2727297A1 (en) * 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh New emulsions for producing medicinal products
EP2299990A1 (de) * 2008-06-09 2011-03-30 Boehringer Ingelheim International GmbH Neue einbettungspartikel für die inhalation
EP2299953B1 (en) * 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
DE102008037324A1 (de) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung
CN102164487A (zh) * 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
CN102448439A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
IN2012DN00570A (pt) 2009-07-14 2015-06-12 Polypid Ltd
BR112012001786A2 (pt) * 2009-07-27 2016-04-12 Cargill Inc "uso de eritritol para a prevenção ou tratamento de hipertensão"
EP2338520A1 (de) * 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
EP2525778B1 (en) 2010-01-19 2018-08-01 Polypid Ltd. Sustained-release nucleic acid matrix compositions
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
BR112013007304B1 (pt) 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
BR112013019335B1 (pt) 2011-02-07 2022-05-31 Scipharm Sàrl Nova composição, método para aumentar o nível de camp em um célula e combinação terapêutica, para o tratamento da fibrose cística
BR112013021732B1 (pt) 2011-02-25 2021-11-30 South Dakota State University Micela estável e utilização da micela estável
PT2701683T (pt) * 2011-04-26 2017-05-03 Vectura Gmbh Administração de iloprost como bólus de aerossol
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
WO2014067699A1 (en) * 2012-10-31 2014-05-08 Activaero Gmbh Administration of aerosolised iloprost
AU2013351934B2 (en) * 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
ES2860975T3 (es) 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
WO2017000083A1 (zh) * 2015-06-30 2017-01-05 上海交通大学 Nicardipine在制备抗肺癌产品中的应用
EP3402347B1 (en) * 2016-01-11 2022-06-29 Arizona Board of Regents on behalf of Arizona State University Ereptiospiration device for medicinal waxes, solids, biopolymers, or highly viscous oils, and cannabinoids
CA3012679C (en) * 2016-01-29 2023-12-12 Mannkind Corporation Dry powder inhaler
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
RU2757903C2 (ru) * 2016-09-15 2021-10-22 Камурус Аб Препараты аналогов простациклина
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
US20240299413A1 (en) 2020-08-07 2024-09-12 Eicos Sciences, Inc. Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration
US20240299414A1 (en) * 2020-08-13 2024-09-12 Eicos Sciences, Inc. Subcutaneous or intramuscular injection formulations of iloprost
EP4267003A1 (en) * 2020-12-22 2023-11-01 Radiometer Medical ApS Blood sampler containing anti-platelet agent and water-soluble matrix material
WO2023154705A1 (en) * 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy
WO2025019625A1 (en) 2023-07-18 2025-01-23 Btg International Inc. Method of using iloprost for treating frostbite

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2882271A (en) * 1959-04-14 Xcixcxh
US466325A (en) * 1892-01-05 Hubert glaus
NL238796A (pt) * 1958-05-07
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
NL137318C (pt) * 1964-06-09
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US3562257A (en) * 1967-10-28 1971-02-09 Tanabe Seiyaku Co Benzothiazepine derivatives
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3773939A (en) * 1971-11-24 1973-11-20 Janssen Pharmaceutica Nv N-arallyl-n'-aralkyl piperazine pharmaceutical compositions
BE795735A (fr) * 1972-03-06 1973-06-18 Cerm Cent Europ Rech Mauvernay Nouvelles ethylenediamines substituees a activite cardiovasculaire
US3985758A (en) * 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
US4154839A (en) * 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
JPS55301A (en) * 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
SE429652B (sv) * 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3048906A1 (de) * 1980-12-19 1982-07-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB2111978B (en) * 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4468972A (en) * 1982-04-19 1984-09-04 Universal Cooperatives, Inc. Flow meter with a motor driven impeller
ATE50987T1 (de) * 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
DE3306123A1 (de) * 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4950680A (en) * 1983-03-31 1990-08-21 Board Of Governors Of Wayne State University Method and compositions for inhibition of tumor cell induced platelet aggregation
US4567175A (en) * 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US4672068A (en) * 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
JPH0779694B2 (ja) * 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
KR890004196B1 (ko) * 1985-07-29 1989-10-27 산텐세이야꾸가부시끼가이샤 신규 벤조티아진 유도체의 제조방법
US4885284A (en) * 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
GB8715238D0 (en) * 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
ATE61588T1 (de) * 1987-08-03 1991-03-15 Delagrange Lab 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US6060069A (en) * 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5239993A (en) * 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
SK51695A3 (en) * 1992-10-19 1995-11-08 Dura Pharma Inc Dry powder medicament inhaler
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
PT994887E (pt) * 1997-07-03 2003-04-30 Elan Drug Delivery Ltd Glicosidos modificados composicoes que compreendem os mesmos e metodos para a sua utilizacao
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6242482B1 (en) * 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
CN1642503A (zh) * 2002-02-07 2005-07-20 拉特格斯·新泽西州立大学 用于药物送递的治疗聚酐化合物
DE10253623B4 (de) * 2002-11-15 2006-03-09 Justus-Liebig-Universität Giessen Bioabbaubare kolloidale Partikel, insbesondere für pulmonale Applikationen

Also Published As

Publication number Publication date
WO2006014930A2 (en) 2006-02-09
CA2574958A1 (en) 2006-02-09
AU2005269465A1 (en) 2006-02-09
NO20071090L (no) 2007-02-26
WO2006014930A3 (en) 2007-02-01
KR20070054644A (ko) 2007-05-29
US20060147520A1 (en) 2006-07-06
EP1796653A2 (en) 2007-06-20
JP2008507585A (ja) 2008-03-13
IL180851A0 (en) 2007-07-04
MX2007000979A (es) 2007-07-11
CN101090714A (zh) 2007-12-19
RU2007106714A (ru) 2008-09-10

Similar Documents

Publication Publication Date Title
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
NO20092637L (no) Fremgangsmater for behandling
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
WO2005074913A3 (en) Compositions and methods for treating contracture
DE60116256D1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2009079451A3 (en) Compositions and methods of promoting wound healing
NO20064584L (no) Tetrahydropyridoindolderivater
NO20063171L (no) Endoparasitisidale sammensetninger for topisk anvendelse
BRPI0510925A (pt) métodos e composições para cicatrização de ferida
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2006063215A3 (en) Methods and compositions for the treatment of pulmonary hypertension of the newborn
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
EP1773363A4 (en) NGNA COMPOSITIONS AND APPLICATION PROCEDURES
NO20092078L (no) Fremgangsmate for behandling av alkoholmisbruk, adiksjon og avhengighet
EA200801296A1 (ru) Способ лечения метаболического синдрома

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO DE: COTHERIX, INC.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]